Cargando…
Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma
The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081058/ https://www.ncbi.nlm.nih.gov/pubmed/32226773 http://dx.doi.org/10.3389/fonc.2020.00282 |
_version_ | 1783508106915872768 |
---|---|
author | Van Gestel, Dirk Dragan, Tatiana Grégoire, Vincent Evans, Mererid Budach, Volker |
author_facet | Van Gestel, Dirk Dragan, Tatiana Grégoire, Vincent Evans, Mererid Budach, Volker |
author_sort | Van Gestel, Dirk |
collection | PubMed |
description | The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes many critical steps including interpretation of diagnostic imaging, image fusion, target volume delineation (tumor, lymph nodes, and organs at risk), and planning. Each step has become highly complex, and precise and rigorous QA throughout the planning process is essential. The ultimate aim is to precisely deliver radiation dose to the target, maximizing the tumor dose and minimizing the dose to surrounding organs at risk, in order to improve the therapeutic index. It is imperative that RT QA programs should systematically control all aspects of the RT planning pathway and include regular end-to-end tests and external audits. However, comprehensive QA should not be limited to RT and should, where possible, also be implemented for surgery, systemic therapy, pathology, as well as other aspects involved in the interdisciplinary treatment of HNC. |
format | Online Article Text |
id | pubmed-7081058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70810582020-03-27 Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma Van Gestel, Dirk Dragan, Tatiana Grégoire, Vincent Evans, Mererid Budach, Volker Front Oncol Oncology The impact of radiotherapy (RT) quality assurance (QA) has been demonstrated by numerous studies and is particularly important for head and neck cancer (HNC) treatment due to the complexity of RT target volumes in this region and the multiple adjacent organs at risk. The RT planning process includes many critical steps including interpretation of diagnostic imaging, image fusion, target volume delineation (tumor, lymph nodes, and organs at risk), and planning. Each step has become highly complex, and precise and rigorous QA throughout the planning process is essential. The ultimate aim is to precisely deliver radiation dose to the target, maximizing the tumor dose and minimizing the dose to surrounding organs at risk, in order to improve the therapeutic index. It is imperative that RT QA programs should systematically control all aspects of the RT planning pathway and include regular end-to-end tests and external audits. However, comprehensive QA should not be limited to RT and should, where possible, also be implemented for surgery, systemic therapy, pathology, as well as other aspects involved in the interdisciplinary treatment of HNC. Frontiers Media S.A. 2020-03-12 /pmc/articles/PMC7081058/ /pubmed/32226773 http://dx.doi.org/10.3389/fonc.2020.00282 Text en Copyright © 2020 Van Gestel, Dragan, Grégoire, Evans and Budach. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Van Gestel, Dirk Dragan, Tatiana Grégoire, Vincent Evans, Mererid Budach, Volker Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title | Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title_full | Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title_fullStr | Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title_full_unstemmed | Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title_short | Radiotherapy Quality Assurance for Head and Neck Squamous Cell Carcinoma |
title_sort | radiotherapy quality assurance for head and neck squamous cell carcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081058/ https://www.ncbi.nlm.nih.gov/pubmed/32226773 http://dx.doi.org/10.3389/fonc.2020.00282 |
work_keys_str_mv | AT vangesteldirk radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma AT dragantatiana radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma AT gregoirevincent radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma AT evansmererid radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma AT budachvolker radiotherapyqualityassuranceforheadandnecksquamouscellcarcinoma |